-+ 0.00%
-+ 0.00%
-+ 0.00%

Maxim Group Maintains Buy on Kazia Therapeutics, Maintains $15 Price Target

Benzinga·06/11/2025 17:32:36
Listen to the news
Maxim Group analyst Jason McCarthy maintains Kazia Therapeutics (NASDAQ:KZIA) with a Buy and maintains $15 price target.